Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intra-articular AS902330 for acute knee cartilage injury
2009-015532-14Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sprifermin in Knee cartilage injury and traumatic knee cartilage injury (4 arms), sponsored by Merck Serono. Primary endpoint: Relative change in cartilage defect volume over 12 months. Started Dec 2009; status: completed.
02
Drugs
sprifermin
03
Conditions
Knee cartilage injurytraumatic knee cartilage injury
Beyond the preview
Go deeper on 2009-015532-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015532-14.